Sign in

CIK 0001677077

  • Emerging growth company

Alzamend Neuro, Inc.

Sign in to watch
Ticker
ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Apr 30
Incorporated
DE
Entity type
Operating
EIN
811822909
Phone
+1 844-722-6333
Business address
480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
  1. 4 Open-market sale Director sold 139,412 shares at an average $2.47 ($344,222)
  2. 4 Open-market sale Director sold 123,366 shares at an average $2.41 ($296,789)
  3. 4 Open-market sale Director sold 79,628 shares at an average $2.31 ($184,156)
  4. 4 Open-market sale Director sold 97,006 shares at an average $2.34 ($226,923)
  5. 4 Open-market sale Director sold 77,009 shares at $2.35 ($180,856)
  6. 4 Open-market sale Director sold 22,991 shares at an average $2.47 ($56,696)
  7. 4 Open-market sale Director sold 129,449 shares at an average $2.28 ($295,532)
  8. 4 Open-market sale Director sold 44,843 shares at an average $2.86 ($128,169)
  9. 4 Open-market sale Director sold 69,137 shares at an average $2.95 ($203,821)
  10. 4 Open-market sale Director sold 1,224 shares at an average $5.06 ($6,196)
  11. 4 Open-market buy Director bought 3,334 shares at $0.99 ($3,285)
  12. 4 Open-market buy Director bought 2,905 shares at $1.02 ($2,969)
  13. 4 Open-market buy Chief Financial Officer bought 5,000 shares at $1.01 ($5,048)
  14. 4 Open-market buy Director bought 5,000 shares at $0.98 ($4,892)
  15. 4 Open-market buy Director bought 5,000 shares at $0.97 ($4,852)
  16. 4 Open-market buy Director bought 5,000 shares at $0.96 ($4,810)
  17. 4 Open-market buy Director bought 100 shares at $0.68 ($68)
  18. 4 Open-market buy Director bought 75 shares at $2.75 ($206)
  19. 4 Open-market buy Director bought 25 shares at $3.74 ($93)
  20. 5 Insider Annual Insider Trading Report

Page 2 of 9 · 170 filings